Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease

Juha O. Rinne, Keith Wesnes, Jeffrey L. Cummings, Pasi Hakulinen, Merja Hallikainen, Jutta Hänninen, Michael Murphy, Henry Riordan, Mika Scheinin, Hilkka Soininen, Juha Rouru

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Introduction ORM-12741 is a novel selective antagonist of alpha-2C adrenoceptors. This trial evaluated the safety and efficacy of ORM-12741 in patients with Alzheimer's disease (AD). Methods A randomized, double-blind, placebo-controlled, exploratory phase 2a trial was conducted in 100 subjects with AD and neuropsychiatric symptoms. Participants were randomized to receive one of two flexible doses of ORM-12741 (30–60 mg or 100–200 mg) or placebo b.i.d. for 12 weeks in addition to standard therapy with cholinesterase inhibitors. Efficacy was assessed primarily with the Cognitive Drug Research (CDR) computerized assessment system and secondarily with the Neuropsychiatric Inventory (NPI). Results A statistically significant treatment effect was seen in one of the four primary CDR system end points, Quality of Episodic Memory (P = .030; not adjusted for multiple comparisons), favoring ORM-12741 over placebo. NPI caregiver distress scores also favored ORM-12741 (P = .034). ORM-12741 was well tolerated. Discussion This is the first clinical trial providing evidence on an acceptable safety profile for ORM-12741 in patients with AD and neuropsychiatric symptoms. In addition, the trial provided hints of potential therapeutic benefit, primarily on episodic memory, in this patient population.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number1
StatePublished - Jan 1 2017

Bibliographical note

Publisher Copyright:
© 2016 Orion Pharma


  • Alpha-2C adrenoceptor antagonist
  • Alzheimer's disease
  • Behavioral and psychological symptoms of dementia
  • Cognition
  • Memory
  • Neuropsychiatric symptoms
  • ORM-12741
  • Randomized trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease'. Together they form a unique fingerprint.

Cite this